Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shenzhen Hepalink Signs Two Deals with ProMetic Life Sciences

publication date: Oct 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenzhen Hepalink Pharma announced it has entered two agreements with ProMetic Life Sciences of Canada. Their total value is $21 million. Hepalink will license ProMetic’s protein technologies for an R&D project, and it will invest $10 million into ProMetic’s common stock. ProMetic said the deals will accelerate its expansion into Asia. More details....

Stock Symbols: (SHE: 002399) (TSX: PLI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners